Search

To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.

A multi-country randomized, placebo-controlled trial of the safety, immunogenicity and efficacy of respiratory syncytial virus (RSV) F-protein nanoparticle vaccine was undertaken in 4,636 pregnant women and their infants. RSV F-protein vaccine was safe and immunogenic in the pregnant women inducing anti-F IgG, palivizumab-competing antibodies and RSV neutralizing antibodies that were transferred to the fetus.

Australian infants who received whole-cell pertussis vaccines were less likely to be diagnosed with food allergy in childhood

No new safety concerns were identified for live attenuated herpes zoster vaccine in this study based on a novel, Australian primary care data source

The findings of this postmarketing assessment of the safety of 2 new enhanced influenza vaccines support confidence in ongoing vaccine use

The P3-MumBubVax intervention is feasible and acceptable in the Australian public antenatal setting

Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme

We found a numerically higher rate of preterm births among women who received 23vPPV in pregnancy compared to unvaccinated pregnant women

The review provides the basis for further research into the effects of acute and chronic UV radiation exposure on skin cells in the context of vaccination

Pathogenic SCN1A variants may be identified in infants with vaccine-proximate febrile seizures